SME Times is powered by   
Search News
Just in:   • WTO sees 2017 global trade growth at 3.6 pc  • Equities fall steepest in 10 months on global cues, weak rupee  • Microsoft support 4,000 start-ups  • Odisha's new export policy soon: CM  • Reliance Home Finance debuts at Rs 107 on NSE 
Last updated: 13 Sep, 2017  

Life Line Screening Expands Product Base to DNA, Clinical Trials

Business Wire India | 13 Sep, 2017
Life Line Screening, a leader in community-based preventive healthcare, is deepening its delivery model of face-to-face patient care to provide access to advanced precision medicine through DNA testing and clinical trials.  

This expansion is a natural outcome of the company’s already rigorous research arm, which has resulted in dozens of papers and presentations that analyze the company’s eight million record database. Research partners include faculty at NYU-Langone Medical Center, Oxford University, and University of California, San Francisco.

 

Life Line Screening pioneered the community-based screening market when it started more than twenty years ago, and helped set the standard for mobile vascular and laboratory testing.

 

The company’s unique in-person consultations, coupled with more than 15,000 community locations across the country, provide a rare opportunity to evaluate individuals for disease risk factors, perform on-site clinical testing, and utilize qualified health professionals such as nurse practitioners to educate consumers about clinical trial opportunities. Life Line Screening has already demonstrated the ability to quickly and effectively leverage its point of care platform to recruit for more than 60 clinical trials – outperforming more traditional approaches by orders of magnitude.

 

Sean Schultz, CEO of Life Line Screening says, “In addition to finding disease early and arming physicians with data for medical management, we are uniquely positioned in the healthcare continuum to disrupt traditional clinical trial recruitment models and help speed the delivery of new medications to market. We screen 50,000 – 60,000 people per month and have a relationship with them over decades. While we are in the early stages of this initiative, we are rapidly developing in sophistication. We have a significant amount of subjective data but more importantly, objective screening data as well. DNA offerings will further enhance the customer experience and provide more fruitful insights to the research community.”

 

“Our goal is to create a medical model that is tailored to the individual patient, with information that enables decisive action specific to that person,” says Schultz. “The advancements in technology are developing fast, and our adaptable model of patient outreach and service delivery allows us to jump ahead of other companies.”

 

 

 

 
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
65.40
63.70
UK Pound
88.60
85.70
Euro
77.95
75.35
Japanese Yen 58.40 56.40
As on 23 Sep, 2017
  Daily Poll
Small traders even below the threshold limit too should register under GST system?
 Yes
 No
 Can't Say
  Commented Stories
» Starting an import export business: Basic guide for beginners(11)
» Export sops: WTO compliance(4)
» GST Council reduces GST rates on 18 handicrafts items(3)
» Committee on Exports formed to monitor issues post GST(2)
» Daily Staples from Daawat Now Offer up to Rs. 75 Paytm Cash(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter